Verrica Pharmaceuticals reported $14.4 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern within one year. Nine-month YCANTH product revenue rose to $15.1 million from $11.6 million.
VRCA · Verrica Pharmaceuticals Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Verrica Pharmaceuticals reported U.S. Wycanth product revenue of $5.7 million in the third quarter of 2026. One Phase III trial completed enrollment, the second exceeded 50% enrollment, and readouts are expected in the first quarter of 2027 and mid-2027.
Verrica Pharmaceuticals Inc. reported record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 57.9% year-over-year. COVE-2 enrollment is complete, with topline data expected in Q1 2027; COVE-3 enrollment exceeds 50%, with topline data expected in mid-2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. YCANTH net product revenue grew 11.9% sequentially and 57.9% year over year with improved gross-to-net yield, while both pivotal common-warts trials advanced toward 2027 readouts. The remaining $15.0 million under the $27.5 million credit facility was unlocked, extending cash runway into the fourth quarter of 2027, but total revenue declined, losses widened, and research and development and selling, general and administrative expenses increased.
- + YCANTH net product revenue reached $5.7 million, up 11.9% sequentially and 57.9% year over year.
- + Enrollment was completed in COVE-2, COVE-3 was more than 50% enrolled, and topline data are expected in the first quarter of 2027 and mid-2027, respectively.
- + The $27.5 million credit facility's remaining $15.0 million was unlocked, extending cash runway into the fourth quarter of 2027.
- + YCANTH product growth was supported by improved gross-to-net yield from reduced co-pay assistance spending.
- + Pooled registrational-trial analyses indicated that YCANTH-treated patients achieved complete clearance approximately four times faster than placebo and at each visit, three times as many treated patients achieved clearance.
- + Verrica is exploring VP-315 development for Gorlin syndrome, an indication with no current FDA-approved products.
- − Total revenue declined to $6.9 million from $14.3 million because the prior-year period included a $10.0 million one-time Torii milestone payment.
- − GAAP net loss widened to $12.4 million, or $0.58 per share, from a $0.3 million loss, or $0.03 per share.
- − Non-GAAP results moved from $1.1 million of income in 2025 to a $10.5 million loss in 2026.
- − Research and development expense rose to $7.6 million from $2.2 million.
- − Selling, general and administrative expenses increased to $10.4 million from $9.4 million.
- − Interest income declined to $45,000 from $0.2 million, primarily because cash balances were lower.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Company's share | 3.7M | three months ended September 30, 2026 filing | — |
| contra-research and development expense | 0.3M | three months ended September 30, 2026 filing | — |
| total program costs incurred under the arrangement | 7.4M | three months ended September 30, 2026 filing | — |
| Non-GAAP net loss non-GAAP | $19M | six months ended June 30, 2026 | — |
| Non-GAAP net loss per share non-GAAP | $0.89 | six months ended June 30, 2026 | — |
| YCANTH dispensed applicator units | 19,626 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRCA
this stock
Verrica Pharmaceuticals Inc.
|
$61.16M | -57.2% | +370.2% | — | 1.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 12
Verrica Pharmaceuticals reported $14.4 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern within one year. Nine-month YCANTH product revenue rose to $15.1 million from $11.6 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRCA | +11.6% | -1.0% | -40.9% | +6.3% | -57.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +9.0% | +0.2% | -41.4% | +6.5% | -67.8% |